VGI Health Technology (XNEC:VTL) Price-to-Operating-Cash-Flow : (As of May. 30, 2024)

View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Price-to-Operating-Cash-Flow?

As of today (2024-05-30), VGI Health Technology's share price is A$0.02. VGI Health Technology does not have enough years/quarters to calculate the Cash Flow from Operations per share for the trailing twelve months (TTM) ended in . 20. Therefore GuruFocus does not calculate Price-to-Operating-Cash-Flow Ratio at this moment.

The historical rank and industry rank for VGI Health Technology's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 0 years, VGI Health Technology's highest Price-to-Operating-Cash-Flow Ratio was 0.60. The lowest was 0.00. And the median was 0.00.

XNEC:VTL's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 26.04
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

VGI Health Technology's Cash Flow from Operations per share for the six months ended in . 20 was A$0.00.

VGI Health Technology Price-to-Operating-Cash-Flow Historical Data

The historical data trend for VGI Health Technology's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology Price-to-Operating-Cash-Flow Chart

VGI Health Technology Annual Data

Trend

Price-to-Operating-Cash-Flow

VGI Health Technology Semi-Annual Data

Price-to-Operating-Cash-Flow

Competitive Comparison of VGI Health Technology's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, VGI Health Technology's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VGI Health Technology's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VGI Health Technology's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where VGI Health Technology's Price-to-Operating-Cash-Flow falls into.

VGI Health Technology Price-to-Operating-Cash-Flow Calculation

VGI Health Technology's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	0.02	/
	=

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

VGI Health Technology Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

VGI Health Technology (XNEC:VTL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003

Website

https://www.vgiht.com

VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines